(FM) Inmunología
Departamento académico
Miguel
Fernández de Sanmamed Gutiérrez
Consultor Médico
Publicaciones en las que colabora con Miguel Fernández de Sanmamed Gutiérrez (68)
2024
-
MHC class I and II-deficient humanized mice are suitable tools to test the long-term antitumor efficacy of immune checkpoint inhibitors and T-cell engagers
Journal for immunotherapy of cancer, Vol. 12, Núm. 9
-
Sequential immunotherapy and targeted therapy for metastatic BRAF V600 mutated melanoma: 4-year survival and biomarkers evaluation from the phase II SECOMBIT trial
Nature Communications, Vol. 15, Núm. 1
-
Short-term cultured tumor fragments to study immunotherapy combinations based on CD137 (4-1BB) agonism
OncoImmunology, Vol. 13, Núm. 1
-
Whole exome sequencing and machine learning germline analysis of individuals presenting with extreme phenotypes of high and low risk of developing tobacco-associated lung adenocarcinoma
eBioMedicine, Vol. 102
2023
-
A first-in-human study of the fibroblast activation protein-targeted, 4-1BB agonist RO7122290 in patients with advanced solid tumors
Science translational medicine, Vol. 15, Núm. 695, pp. eabp9229
-
CD137 (4-1BB)-Based Cancer Immunotherapy on Its 25th Anniversary
Cancer discovery, Vol. 13, Núm. 3, pp. 552-569
-
Intratumoral BO-112 in combination with radiotherapy synergizes to achieve CD8 T-cell-mediated local tumor control
Journal for immunotherapy of cancer, Vol. 11, Núm. 1
-
Intratumoral Gene Transfer of mRNAs Encoding IL12 in Combination with Decoy-Resistant IL18 Improves Local and Systemic Antitumor Immunity
Cancer immunology research, Vol. 11, Núm. 2, pp. 184-198
-
Sequencing of Ipilimumab Plus Nivolumab and Encorafenib Plus Binimetinib for Untreated BRAF -Mutated Metastatic Melanoma (SECOMBIT): A Randomized, Three-Arm, Open-Label Phase II Trial
Journal of Clinical Oncology, Vol. 41, Núm. 2, pp. 212-221
-
mRNAs encoding IL-12 and a decoy-resistant variant of IL-18 synergize to engineer T cells for efficacious intratumoral adoptive immunotherapy
Cell Reports Medicine, Vol. 4, Núm. 3
2022
-
A Therapeutically Actionable Protumoral Axis of Cytokines Involving IL-8, TNFα and IL-1β
Cancer Discovery, Vol. 12, Núm. 9, pp. 2140-2157
-
Charting roadmaps towards novel and safe synergistic immunotherapy combinations
Nature Cancer, Vol. 3, Núm. 6, pp. 665-680
-
Soluble CD137 as a dynamic biomarker to monitor agonist CD137 immunotherapies
Journal for immunotherapy of cancer, Vol. 10, Núm. 3
-
Three-dimensional colon cancer organoids model the response to CEA-CD3 T-cell engagers
Theranostics, Vol. 12, Núm. 3, pp. 1373-1387
2021
-
A burned-out cd8+ t-cell subset expands in the tumor microenvironment and curbs cancer immunotherapy
Cancer Discovery, Vol. 11, Núm. 7, pp. 1700-1715
-
Antitumor efficacy and reduced toxicity using an anti-CD137 Probody therapeutic
Proceedings of the National Academy of Sciences of the United States of America, Vol. 118, Núm. 26
-
CD137 (4-1BB) costimulation of CD8+ T cells is more potent when provided in cis than in trans with respect to CD3-TCR stimulation
Nature Communications, Vol. 12, Núm. 1
-
Consolidating radiotherapy with immunotherapy
Clinical Cancer Research, Vol. 27, Núm. 20
-
Differential Interleukin-8 thresholds for chemotaxis and netosis in human neutrophils
European Journal of Immunology, Vol. 51, Núm. 9, pp. 2274-2280
-
Heterogenous presence of neutrophil extracellular traps in human solid tumours is partially dependent on IL-8
Journal of Pathology, Vol. 255, Núm. 2, pp. 190-201